Nurix Therapeutics, Inc. (NRIX) Income Statement
NRIX FY2025 at a glance
Fiscal year ended November 30, 2025 · U.S. dollarsNRIX revenue and net income
Where NRIX's revenue goes
FY2025Each bar shows an amount and its share of revenue. NRIX kept −314.9% of revenue as net income.
NRIX profit margins
NRIX growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +54.0% | +29.5% | +36.3% | — |
| Gross profit | — | +19.0% | +29.6% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NRIX quarterly EPS vs estimates
Nurix Therapeutics beat the analyst EPS estimate in 5 of the last 8 quarters.
NRIX income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84.0M | $54.5M | $77.0M | $38.6M | $29.8M | $17.8M | $31.1M | $37.4M |
| Cost of revenue | $18.9M | $221.6M | $189.1M | $10.8M | $6.1M | $66.5M | $45.0M | $40.5M |
| Gross profit | $65.1M | −$167.1M | −$112.2M | $38.6M | $29.8M | $17.8M | −$13.9M | −$3.1M |
| Research & development | $308.2M | $221.6M | $189.1M | $184.5M | $116.4M | $66.5M | $45.0M | $40.5M |
| Sales, general & admin | $52.7M | $45.9M | $42.9M | $38.0M | $31.2M | $16.3M | $8.3M | $6.7M |
| Total operating expenses | $350.8M | $45.9M | $42.9M | $222.5M | $147.6M | $82.8M | $8.3M | $6.7M |
| Operating income | −$285.7M | −$213.0M | −$155.1M | −$183.9M | −$117.9M | −$65.0M | −$22.2M | −$9.7M |
| Interest income | $22.0M | $19.7M | $11.1M | $3.5M | $823,000 | $1.2M | $776,000 | $818,000 |
| Interest expense | — | — | — | $14.3M | $6.9M | $3.4M | $776,000 | $818,000 |
| Income before taxes | −$263.7M | −$193.3M | −$143.9M | −$180.4M | −$117.1M | −$63.8M | −$21.5M | −$8.9M |
| Income taxes | $760,000 | $270,000 | $13.5M | −$14.3M | $131,000 | −$20.5M | $239,000 | $507,000 |
| Net income | −$264.5M | −$193.6M | −$143.9M | −$166.0M | −$117.2M | −$43.2M | −$21.7M | −$9.4M |
| EBITDA | −$244.8M | −$176.9M | −$130.3M | −$173.1M | −$111.8M | −$62.8M | −$19.9M | −$6.8M |
| EPS (diluted) | −$3.04 | −$2.89 | −$2.65 | −$3.73 | −$2.73 | −$4.10 | −$1.04 | −$3.14 |
| Gross margin | 77.5% | −306.3% | −145.7% | 100.0% | 100.0% | 100.0% | −44.7% | −8.2% |
| Operating margin | −340.2% | −390.5% | −201.4% | −476.0% | −396.3% | −364.7% | −71.5% | −26.0% |
| Net margin | −314.9% | −354.9% | −187.0% | −429.9% | −393.9% | −242.7% | −69.7% | −25.2% |
| Aug '26 | May '26 | Feb '26 | Nov '25 | Aug '25 | May '25 | Feb '25 | Nov '24 | Aug '24 | May '24 | Feb '24 | Nov '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $673.1M | $9.0M | $6.3M | $13.6M | $7.9M | $44.1M | $18.5M | $13.3M | $12.6M | $12.1M | $16.6M | $15.2M |
| Cost of revenue | $2.1M | $3.9M | $84.1M | $4.6M | $5.0M | $78.1M | $69.7M | $67.2M | $55.5M | $48.9M | $50.0M | $49.7M |
| Gross profit | $670.9M | $5.2M | −$77.9M | $8.9M | $2.9M | −$34.0M | −$51.2M | −$53.9M | −$42.9M | −$36.8M | −$33.4M | −$34.6M |
| Research & development | $79.3M | $87.7M | $84.1M | $80.9M | $86.1M | $78.1M | $69.7M | $67.2M | $55.5M | $48.9M | $50.0M | $49.7M |
| Sales, general & admin | $34.4M | $15.6M | $14.6M | $13.6M | $13.2M | $14.3M | $11.7M | $10.7M | $11.7M | $11.7M | $11.8M | $10.8M |
| Total operating expenses | $111.5M | $99.4M | $14.6M | $92.0M | $94.3M | $14.3M | $11.7M | $10.7M | $11.7M | $11.7M | $11.8M | $10.8M |
| Operating income | $559.5M | −$94.2M | −$92.5M | −$83.1M | −$91.4M | −$48.3M | −$62.9M | −$64.7M | −$54.6M | −$48.5M | −$45.2M | −$45.3M |
| Interest income | — | $4.4M | $5.3M | $4.9M | $5.0M | $5.6M | $6.5M | $6.1M | $5.7M | $4.1M | $3.8M | $3.4M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | — | $7.9M |
| Income before taxes | $563.4M | −$89.8M | −$87.2M | −$78.2M | −$86.4M | −$42.7M | −$56.4M | −$58.5M | −$48.9M | −$44.5M | −$41.4M | −$42.0M |
| Income taxes | $13.6M | −$271,000 | — | — | — | $760,000 | — | $8,000 | $82,000 | $90,000 | $90,000 | $7.9M |
| Net income | $549.8M | −$89.5M | −$87.2M | −$78.2M | −$86.4M | −$43.5M | −$56.4M | −$58.5M | −$49.0M | −$44.5M | −$41.5M | −$42.0M |
| EBITDA | $565.6M | −$86.0M | −$83.4M | −$73.6M | −$81.4M | −$40.5M | −$54.0M | −$57.3M | −$46.5M | −$42.1M | −$39.4M | −$41.4M |
| EPS (diluted) | $4.73 | −$0.81 | −$0.79 | −$0.82 | −$1.03 | −$0.52 | −$0.67 | −$0.75 | −$0.67 | −$0.71 | −$0.76 | −$0.77 |
| Gross margin | 99.7% | 57.4% | −1,245.8% | 65.9% | 36.7% | −77.3% | −277.5% | −406.1% | −340.7% | −304.6% | −201.5% | −227.9% |
| Operating margin | 83.1% | −1,041.7% | −1,479.4% | −612.0% | −1,157.7% | −109.7% | −340.7% | −486.7% | −433.8% | −401.4% | −272.6% | −299.1% |
| Net margin | 81.7% | −990.1% | −1,394.3% | −576.1% | −1,094.8% | −98.7% | −305.4% | −440.7% | −388.9% | −368.4% | −250.3% | −276.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NRIX's financial statements (latest annual report filed January 28, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NRIX financial results
In fiscal year 2025 (ended November 30, 2025), Nurix Therapeutics reported revenue of $84.0 million, up 54.0% from the year before. It had a net loss of $264.5 million, a net profit margin of −314.9%. Diluted earnings per share came to −$3.04. Over five years revenue grew at an average rate of 36.3% a year.
See the NRIX stock overview for the latest quote and news, or the NRIX chart for price history and technical indicators.
NRIX income statement FAQ
What is Nurix Therapeutics's annual revenue?
Nurix Therapeutics reported total revenue of $84.0 million for fiscal year 2025, which ended on November 30, 2025. That was up 54.0% from $54.5 million the previous year.
Is Nurix Therapeutics profitable?
No. Nurix Therapeutics reported a net loss of $264.5 million in fiscal 2025, a net profit margin of −314.9%; its operating margin was −340.2%.
What is Nurix Therapeutics's gross margin?
Nurix Therapeutics's gross margin was 77.5% in fiscal 2025: for every $100 of revenue, Nurix Therapeutics kept $78 after the direct cost of its products and services.
How much does Nurix Therapeutics spend on research and development?
Nurix Therapeutics spent $308.2 million on research and development in fiscal 2025, 366.9% of revenue.
How fast is Nurix Therapeutics growing?
Revenue grew 36.3% a year on average over the last five fiscal years, from $17.8 million to $84.0 million.
What are Nurix Therapeutics's earnings per share?
Nurix Therapeutics earned $-3.04 per diluted share in fiscal 2025, compared with $-2.89 a year earlier.
When does Nurix Therapeutics's fiscal year end?
Nurix Therapeutics's fiscal year ends in November. The latest annual report covers the year ended November 30, 2025 and was filed on January 28, 2026.